BioPharma Dive September 16, 2024
Amy Baxter

Legislation that passed the House of Representatives passed the Biosecure Act last week would force U.S. biotechs to cut ties with five Chinese contract partners.

Some of the most widely used drug contractors are based in China. But the U.S. biopharmaceutical industry may eventually be pushed to cut ties with those partners if the Biosecure Act, which passed in the House of Representatives last week, becomes law.

The act would effectively prohibit U.S. companies from doing business with five Chinese firms, including WuXi AppTec, Complete Genomics and MGI Tech. In the House’s version, companies with existing contracts are given eight years to sever ties. The bill also allows Congress to add more companies to its list as it weighs perceived...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
National Health Expenditures In 2023: Faster Growth As Insurance Coverage And Utilization Increased
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
Health care package winners and losers
A New Weight Loss Drug With No Side Effects? Yes…So Far
The AI Advantage: Reimagining the Future of Drug Development

Share This Article